--- title: "Pharmaceutical Stocks To Watch Today - November 27th" type: "News" locale: "en" url: "https://longbridge.com/en/news/267731104.md" description: "Eli Lilly and Company, AbbVie, and PTC Therapeutics are highlighted as top pharmaceutical stocks to watch today by MarketBeat's stock screener tool. These companies have had the highest trading volumes recently. Eli Lilly focuses on diabetes and obesity treatments, AbbVie on autoimmune and cancer therapies, and PTC Therapeutics on rare disorders. Pharmaceutical stocks are high-risk, high-reward investments due to factors like clinical trials and regulatory approvals." datetime: "2025-11-27T18:54:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/267731104.md) - [en](https://longbridge.com/en/news/267731104.md) - [zh-HK](https://longbridge.com/zh-HK/news/267731104.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/267731104.md) | [繁體中文](https://longbridge.com/zh-HK/news/267731104.md) # Pharmaceutical Stocks To Watch Today - November 27th - MarketBeat Week in Review – 11/24 - 11/28 Eli Lilly and Company, AbbVie, and PTC Therapeutics are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and sell prescription medicines and related therapies, including traditional drugmakers and many biotech firms. Investors view them as potentially high-reward but high-risk because valuations hinge on clinical trial results, regulatory approvals, patent protection, and long development timelines, leading to event-driven volatility. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days. Get **Eli Lilly and Company** alerts: ## Eli Lilly and Company (LLY) Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. - A Trillion-Dollar Pill: Eli Lilly Broke the Healthcare Ceiling Read Our Latest Research Report on LLY ## AbbVie (ABBV) AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. - A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves Read Our Latest Research Report on ABBV ## PTC Therapeutics (PTCT) PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Read Our Latest Research Report on PTCT ## Featured Articles - MarketBeat's Top Five Stocks to Own in November 2025 - Is CrowdStrike Ready to Rally After Its Recent Pullback? - SanDisk Joins the S&P 500: Inside the Index Effect Rally - Amazon Enters Correction Zone—Time to Panic, or to Load Up? - Tesla Just Got Called a “Must Own” Stock—Here’s Why - Why Gold Loves Trump as Much as Trump Loves Gold _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Eli Lilly and Company Right Now? Before you consider Eli Lilly and Company, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list. While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [Eli Lilly and Company (LLY.US)](https://longbridge.com/en/quote/LLY.US.md) - [PTC Therapeutics, Inc. (PTCT.US)](https://longbridge.com/en/quote/PTCT.US.md) - [AbbVie Inc. (ABBV.US)](https://longbridge.com/en/quote/ABBV.US.md) ## Related News & Research - [Is It Time To Reassess PTC Therapeutics (PTCT) After Mixed Multi Year Share Performance?](https://longbridge.com/en/news/280885338.md) - [Eli Lilly opposes push to pass Trump's drug pricing deals into law, CEO says](https://longbridge.com/en/news/281407286.md) - [Eli Lilly Says Long-Term Data Shows Eczema Treatment Provides Up to Four Years of Disease Control](https://longbridge.com/en/news/280800696.md) - [Traders Buy High Volume of Eli Lilly and Company Call Options (NYSE:LLY)](https://longbridge.com/en/news/281412176.md) - [BUZZ-Street View: Lilly's $7.8 billion Centessa buyout validates sleep‑drug market](https://longbridge.com/en/news/281367948.md)